MODERNA CELEBRATES CONSTRUCTION COMPLETION OF CANADIAN MRNA MANUFACTURING FACILITY

Moderna has announced the completion of its state-of-the-art mRNA manufacturing facility in Laval, Quebec. This facility, built in partnership with the Canadian federal government and supported by Investissement Québec, is expected to begin manufacturing respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals. The project aims to bolster Canada’s preparedness for future pandemics, create high-skilled jobs, and contribute to Canada’s position as an mRNA centre of excellence.